Nektar Therapeutics
NKTR
$0.7955
$0.05487.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 56.91% | 42.69% | 42.30% | 57.61% | 25.03% |
| Total Depreciation and Amortization | -43.81% | -38.89% | -37.90% | -38.63% | -40.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -157.44% | -113.80% | -100.17% | -97.22% | 88.63% |
| Change in Net Operating Assets | 68.71% | 101.75% | 91.77% | -46.05% | -4,152.85% |
| Cash from Operations | 8.77% | 13.13% | 28.39% | 29.50% | 36.64% |
| Capital Expenditure | -69.71% | -9.30% | 52.41% | 69.10% | 84.76% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -90.57% | -90.57% | -90.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -43.49% | -32.18% | -46.70% | -55.61% | -61.16% |
| Cash from Investing | 2.15% | -38.51% | -49.33% | -57.19% | -61.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 293.33% | -61.16% | -71.90% | -94.21% | -96.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 140,293.33% | 34,649.59% | 34,638.84% | 7,274.21% | -98.01% |
| Foreign Exchange rate Adjustments | -106.45% | -126.61% | -12.50% | 103.40% | 118.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.95% | 14.75% | 15.02% | -415.92% | -184.04% |